

MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934

Balance Sheet As On 31st March, 2022

Particulars	Note No.	As at 31st March 2022 Rs.(Hundred)
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	3	1000.00
(b) Reserves and surplus	4	58.19
(c) Money Received against share warrants		-
2 Share application money pending allotments		-
3 Non-current liabilities		
(a) Long-term borrowings		-
(b) Deferred tax liabilities (net)		-
(c) Other Long Term Liabilities		-
(d) Long term provision		-
4 Current liabilities		
(a) Short Term Borrowings		-
(b) Trade payables	5	
(A) total outstanding dues of micro enterprises and small enterprises		221.31
(B) total outstanding dues of Creditors other than micro enterprises and small enterprises		-
(c) Other current liabilities	6	15.00
(d) Short-term provisions	7	166.23
TOTAL		1460.73
B ASSETS		
1 Non-current assets		
(a) (i) Property, Plant and Equipment		-
(ii) Intangible assets		-
(iii) Capital Work in progress		-
(iv) Intangible Assets under Development		-
(b) Non-current investments		-
(c) Deferred Tax Assets		45.76
(d) Long term loans and Advances		-
(e) Other Non Current Assets		-
2 Current assets		
(a) Current Investments		-
(b) Inventories		-
(c) Trade receivables		-
(d) Cash and cash equivalents	8	1389.97
(e) Short-term loans and advances	9	25.00
(f) Other Current Assets		-
TOTAL		1460.73

See accompanying notes forming part of the financial statements

2

In terms of our report attached.

For MNJ and Associates

Chartered Accountants

FRN: 130772W

R.R. Shah
CA Rajendra Shah

(Partner)

Membership No: 111647

Place: Mumbai

Date : 19/07/2022

UDIN : 22111647ANEVIE5021



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED

For MEDUCLINIC HEALTHCARE PRIVATE LIMITED

Priti D Shah

Priti D Shah

(Director)

DIN:08124259

Rupanshi D Shah
Director/Authorised Signatory

Rupanshi D Shah

(Director)

DIN:08716765

MEDUCLINIC HEALTHCARE PRIVATE LIMITED		
CIN: U80301MH2022PTC376934		
STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE PERIOD ENDED 31st MARCH 2022		
Particulars	Note No.	31st March 2022 Rs.(Hundred)
I Revenue from operations (gross)	10	400.00
Revenue from operations (net)		400.00
II Other Income		0.00
III Total Income (I+II)		400.00
IV Expenses		
Employee benefits expenses		-
Finance costs		-
Depreciation and amortisation expenses		-
Other expenses	11	321.34
Total Expenses		321.34
V Profit/(Loss) before exceptional and extraordinary item and tax		78.66
VI Exceptional Items		-
VII Profit/(Loss) before extraordinary item and tax		78.66
VIII Extraordinary Items		0.00
IX Profit/(Loss) before Tax		78.66
X Tax Expense:		
(a) Current tax expense		66.23
(b) Deferred tax (Assets)		-45.76
XI Profit / (Loss) for the period from continuing operations		58.19
XII Profit / (Loss) from discontinuing operations		-
XIII Tax from discontinuing operations		-
XIV Profit/ (Loss) from discontinuing operations		-
XV Profit/(Loss) for the Period		58.19
XVI Earning per equity share:		
(1) Basic		0.58
(2) Diluted		0.58

In terms of our report attached.
For MNJ And Associates
Chartered Accountants
FRN: 130772W

For MEDUCLINIC HEALTHCARE PRIVATE LIMITED
For MEDUCLINIC HEALTHCARE PRIVATE LIMITED

R. R. Shah
CA Rajendra Shah
(Partner)
Membership No: 111647
Place: Mumbai
Date : 19/07/2022
UDIN : 22111647ANEV1E5021



P. D. Shah
Rupanshi Shah
Director/Authorised Signatory

Priti D Shah
(Director)
DIN:08124259

Rupanshi D Shah
(Director)
DIN:08716765

MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934

NOTES FOR FINANCIAL STATEMENTS FOR THE PERIOD FROM 16th MARCH, 2022 TO 31st MARCH, 2022

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON FINANCIAL STATEMENTS

NOTE 1 : CORPORATE INFORMATION

The Company is incorporated on 16th February 2022. The Company is engaged in business of providing Counselling, Guidance coaching classes, infrastructure and support services to students for pursuing higher studies in field of medical in India and Abroad.

NOTE 2 : SIGNIFICANT ACCOUNTING POLICIES

BASIS OF ACCOUNTING AND PREPARATION OF FINANCIAL STATEMENTS -

The financial statements have been prepared under the historical cost convention in accordance with the applicable accounting principles in India, Accounting Standard notified under sub-section (2) of Section 2 of the Companies Act 2013 and relevant provisions as adopted consistently of the Companies Act , 2013,

Accounting policies not specifically referred to otherwise are consistent with generally accepted accounting principles.

The Company generally follows mercantile system of accounting and all income and expenditure items having a material bearing on the financial statements are recognised on accrual basis.

USE OF ESTIMATES

The preparation of Financial Statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Differences between the actual results and estimates are recognised in the period in which the results are known/materialised.



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED

Pran. Dhongaj

Rupankhi Shah
Director/Authorised Signatory

REVENUE RECOGNITION

Revenue in respect of educational and training programme or advisory services aspiring to go to abroad or in India received from customer is recognized in profit and loss over the period of contract in proportion to the stage of completion of the services at the reporting date.

EARNING PER SHARE

The Company reports basic earning per share in accordance with AS-20 for "Earning Per share" issued by the ICAI. Basic earning per share has been computed by dividing net profit after tax by the weighted average number of equity shares outstanding for the year.

PROVISIONS AND CONTINGENCIES

A provision is recognised when the company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which reliable estimates can be made. Provision are not discounted to their present value and are determined based on the best estimates at the Balance Sheet date.

TAXES ON INCOME

Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the provisions of Income Tax Act, 1961. Deferred tax is recognised, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax assets in respect of depreciation is recognised if there is virtual certainty that there will be sufficient future taxable income available.



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED
P. Dhanraj S. Sankar
Director/Authorised Signatory

MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934

Notes to financial statements for the period ended 31 March 2022

NOTE 12 : AUDITOR REMUNERATION:

Audit and other fees include payment to Auditor

	<u>As at 31/03/2022</u> Rs.(Hundred)
Audit fees	100.00
	<hr/> <hr/> 100.00

NOTE 13 : EARNING PER SHARE

Disclosure as required by the Accounting Standard - 20 " Earning Per Share"

As at 31/03/2022

Profit after taxation attributable to equity shareholders

As per Profit & Loss account (A)	Rs.	58.19
Equity shares outstanding	Nos.	100.00
Weighted Average Equity shares (B)	Nos.	100.00
Earning per share - basic/ diluted (A/B) (face value - Rs. 10 per share)	Rs.	0.58

NOTE 14 : RELATED PARTIES TRANSACTION:

**Related Party Disclosure as required by-
Accounting Standard -18 Related Party Disclosures**

(A) Key Management Personnel

Priti D Shah - Director

Rupanshi Shah - Director

Note : There is no related party transactions are done in the current period

NOTE 15 : In the opinion of the Directors, the Current Assets, Loans and Advances are approximately of the value as stated, if realised in the ordinary course of business and provision for all known liabilities of the company has been made in the books of accounts and the same is neither in excess nor less than the amounts considered reasonably necessary.



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED

Priti Dhanraj

Rupanshi Shah
Director/Authorised Signatory

NOTE 16 : Ratio Analysis

Ratio Analysis	Numerator	Denominator	Current year	Previous year	% Variance	Refer Note
Current Ratio	Current Assets	Current Liabilities	7.81	NA	0	
Debt-Equity Ratio	Total Debt	Total Equity	-	NA	0	
Debt Service Coverage Ratio	Earnings available for debt service	Debt Service	-	NA	0	
Return on Equity Ratio	Net Profits after taxes – Preference Dividend (if any)	Average Shareholder's Equity	0.58	NA	0	
Inventory Turnover Ratio	Cost of goods sold OR sales	Average Inventory	NA	NA	NA	
Trade Receivables Turnover Ratio	Net Credit Sales	Avg. Accounts Receivable	-	NA	0	
Trade Payables Turnover Ratio	Net Credit Purchases	Average Trade Payables	-	NA	0	
Net Capital turnover Ratio	Net Sales	Working Capital	0.43	NA	0	
Net Profit Ratio	Net Profit	Net Sales	0.15	NA	0	
Return on Capital employed	Earning before interest and taxes	Capital Employed	0.79	NA	0	
Return on Investment						
Quoted	Income generated from investments	Time weighted average investments	NA	NA	NA	
Unquoted	Income generated from investments	Time weighted average investments	NA	NA	NA	

Based on the information available with the company, outstanding dues as on 31/03/2022 is Rs. 22131/- (as on 31/03/2021 - Rs. NIL) towards Micro & Small Enterprise, as defined in the Micro, Small & Medium Enterprises Development Act, 2006. The above information regarding Micro & Small Enterprises has been determined to the extent such parties have been identified on the basis of information available with the company.

NOTE 17 :

NOTE 18 : Details of dues to micro and small enterprises as defined under the MSMED Act 2006 *

31st March 2022

- | | |
|---|-------|
| a. The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each | |
| - Principal amount due to micro and small enterprises | 22131 |
| - Interest due on above | - |
| b. The amount of interest paid by the buyer in terms of section 16 of the Micro and Small enterprise | - |
| c. The amount of interest due and payable for the period of delay in making payment (which have been paid | - |
| d. The amount of interest accrued and remaining unpaid at the end of each accounting year; | - |
| e. The amount of further interest remaining due and payable even in the succeeding years, until such date | - |

NOTE 19 : This is being the first year, figures have been provided since incorporation of the company till year end.

In terms of our report attached.
For MNJ and Associates
Chartered Accountants
FRN: 130772W

For MEDUCLINIC HEALTHCARE PRIVATE LIMITED
For MEDUCLINIC HEALTHCARE PRIVATE LIMITED

R.R. Shah
CA Rajendra Shah
(Partner)
Membership No: 111647
Place: Mumbai
Date : 19/07/2022
UDIN : 22111647ANEVIE5021



Priti D Shah
Priti D Shah
(Director)
DIN:08124259

Rupanshi D Shah
Rupanshi D Shah
(Director)
DIN:08716765

MEDUCLINIC HEALTHCARE PRIVATE LIMITED
CIN: U80301MH2022PTC376934
NOTES ANNEXED TO AND FORMING PART OF THE BALANCE SHEET

Note 3 : SHARE CAPITAL

Particulars	As at 31st March 2022 Rs.(Hundred)	
	Number of shares	Rs.
(a) Authorised 100000 Equity shares of Rs.10/- each with voting rights	1000.00	10000.00
(b) Issued, Subscribed and Paid up 10000 Equity shares of Rs.10/- each with voting rights	100.00	1000.00
Total	100.00	1000.00

Note :

Reconciliation of the shares

Equity Shares

At the beginning of the year
 Issued during the year
 - Issued for cash
 - Right Issue
 - Bonus Issue
 Outstanding at the end of the year

	As at 31st March 2022	
	In Nos.	Amount
	-	-
	-	-
	100.00	1000.00
	-	-
	-	-
	100.00	1000.00

2) Details of Shareholding of Promoters


Promoter Name	Nos. of Shares	% of Total shares	% change during the year
Moxsh Overseas Educon Private Limited	100.00	100.00%	NA

3) Terms/ Rights attached to Equity Shares

- The company has only one class of shares having a par value at Rs. 10/- per shares. Each holder of Equity Shares is Entitled to one Vote per Share.
- In the event of liquidation of the company, the holders of equity shares will be entitled to receive assets (after repayment of liability) in proportion to the number of equity shares held by the shareholders.

4) Details of Share Holding more than 5 % shares in the Company

Equity Shares of Rs. 10/- each Fully Paid up	As at 31st March 2022	
	In Nos.	% holding in the class
Moxsh Overseas Educon Private Limited	100.00	100.00%



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED
P. D. Dhonajy
Rupam Bishab
Director/Authorised Signatory

MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934

NOTES ANNEXED TO AND FORMING PART OF THE BALANCE SHEET**Note 4 : RESERVES AND SURPLUS**

Particulars	As at
	31st March 2022
	Rs.(Hundred)
(A) Securities premium account	
Opening balance	-
Closing balance	-
(B) Surplus / (Deficit) in Statement of Profit and Loss	
Opening balance	-
Add: Profit / (Loss) for the year	58.19
Less:- Loss Due to Change in Rate of Depreciation as per Company Act 2013	-
Closing balance	58.19
Total	58.19

Note 6 : OTHER CURRENT LIABILITIES

Particulars	As at
	31st March 2022
	Rs.(Hundred)
Creditors For Advance	15.00
Total	15.00

Note 7 : SHORT TERM PROVISIONS

Particulars	As at
	31st March 2022
	Rs.(Hundred)
(a) Provision for employee benefits	-
(b) Provision - for TAX	
Provision for Income Tax(Current Years)	66.23
(c) Provision - Others	
Audit Fees Payable	100.00
Total	166.23



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED

P. DhanrajRupam Chhabra
Director/Authorised Signatory

MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934

NOTES ANNEXED TO AND FORMING PART OF THE BALANCE SHEET**Note 8 : CASH AND CASH EQUIVALENTS**

Particulars	As at
	31st March 2022
	Rs.(Hundred)
A) Cash In Hand	100.00
B) Bank Balance	1289.97
Total	1389.97

Note 9 : SHORT TERM LOANS AND ADVANCES

Particulars	As at
	31st March 2022
	Rs.(Hundred)
Others	25.00
Total	25.00



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED

P. N. DhanyajyRupamkishab
Director/Authorised Signatory

MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934

NOTES ANNEXED TO AND FORMING PART OF THE BALANCE SHEET

Note 5 : TRADE PAYABLES

Figures For the Current Reporting Period

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	221.31	-	-	-	221.31
Others	-	-	-	-	-
Dispute dues-MSME	-	-	-	-	-
Dispute dues Others	-	-	-	-	-
Total	221.31	-	-	-	221.31



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED
Per Pranishtha Rupankishor
Director/Authorised Signatory

Note 10 : REVENUE FROM OPERATIONS	
Particulars	31st March 2022
	Rs.(Hundred)
Sale of Services	400.00
Total - Sales	400.00
Note 11 : OTHER EXPENSES	
Particulars	31st March 2022
	Rs.(Hundred)
Bank Charges	0.03
Audit Fees	100.00
Office Expenses	1.31
Preliminary Expenses	220.00
Total	321.34



For MEDUCLINIC HEALTHCARE PRIVATE LIMITED
Ravi Dhonafey Rupaichhat
 Director/Authorised Signatory

MEDUCLINIC HEALTHCARE PRIVATE LIMITED
FY : 2021-22

AS-22 TAXES ON INCOME

CALCULATION OF DEFERRED TAX ASSETS / LIABILITIES

<u>During the Year</u>	2021-22	
Depreciation		
As per Companies Act	-	
As Per Income Tax Act	-	
Timing Difference due to Current Yr. Deprn.	-	
Tax @26%	-	
Incorporation Expenses		
As per Companies Act	22,000.00	
As Per Income Tax Act	4,400.00	
Timing Difference due to incorporation Expenses	17,600.00	
Tax @26%	4,576.00	
Closing Balance of Fixed Assets as per Companies Act	-	
Closing Balance of Fixed Assets as per Income Tax Act	-	
Timing Difference	-	
Deferred Tax LIABILITY as on 31.03.2018(Deprn)	-	

Calculation of Provision for Current Tax

Profit as per P/L A/C Before Tax	7,866.05
Add: Depreciation as per Companies Act	-
Add: Preliminary Expenses	22,000.00
	<u>29,866.05</u>
Less: Depreciation as per Income Tax Act	-
Less : Disallowances u/s 40(a)(ia) of last year now allowed	-
Less : Allowances under section 35D	4,400.00
	<u>25,466.05</u>
Taxable Profit	25,466.05
Tax @ 25.%	6,366.51
Add: Surcharge 7.5%	-
	6,366.51
Add: Edu Cess 4%	254.66
	<u>6,623.00</u>

AS-22 TAXES ON INCOME

CALCULATION OF DEFERRED TAX ASSETS / LIABILITIES

	Depreciation	Incorpoartion Expenses	Expenses disallowe u/s 40(a)(ia)	Share capital increase exp	Total
Opening balance of Deferred tax Assets / (liabilities)	-		-	-	-
Add: Depreciation difference	-	4,576.00			4,576.00
Less : reversal of deferred tax asset on Depreciation	-				-
Less : reversal of deferred tax asset on exp -wrongly created					-
Less: Defered tax asset on expenses disallowed to be allowed in next year					-
Less :Deferred tax asset on share capital increase expenses					-
Closing balance of Deferred tax asset / (liabilities)	-	4,576.00	-	-	4,576.00
Difference to be created in current year					4,576.00

For MEDUCLINIC HEALTHCARE PRIVATE LIMITED


Director/Authorised Signatory

MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934; Email: medushop.priti@gmail.com

Registered Office: 0-159, Floor-1, Kalyandas Udyog Bhavan, Sh Tandel Marg, Near
Century Bhavan, Mumbai - 400025

DIRECTORS' REPORT

To
The Members,
Meduclinic Healthcare Private Limited,
(CIN: U80301MH2022PTC376934)

Your Directors are pleased to present the **First Annual Report** together with the Audited Financial Statements and Auditors' report thereon for the year ended March 31, 2022.

1. FINANCIAL RESULTS:

The operating results of your Company for the **First Accounting Year** ended on March 31, 2022 are as follows:

Particulars	For the year ended March 31, 2022 (Rs.)
Total Revenue	40,000.00
Total Income	0
Total Expenses	32,133.95
Profit/(Loss) before Tax	7,866.05
Current tax	6,623.00
Deferred tax	(4,576.00)
Profit / (Loss) after tax	5,819.05
Earnings Per Share	0.58

2. INCORPORATION OF COMPANY

Your Company was Incorporated on February 16, 2022 with the Registrar of Companies, Mumbai and accordingly the first financial year of the Company is from February 16, 2022 to March 31, 2022.

3. CONSOLIDATED FINANCIAL STATEMENTS

Company doesn't have any subsidiaries so there is no need to prepare consolidated financial statement for the **Financial Year ended March 31, 2022**.

4. OPERATIONAL REVIEW

The Company has reported an **Net Profit of Rs. 5,819.05/-** during the current year. There has been no change in the nature of business of the Company. There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.



P.D.S.L.

MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934; Email: medushop.priti@gmail.com

Registered Office: 0-159, Floor-1, Kalyandas Udyog Bhavan, Sh Tandel Marg, Near Century Bhavan, Mumbai – 400025

5. DIVIDEND:

In view of the planned business growth, your Directors deem it proper to preserve the resources of the Company for its activities and therefore, do not propose any dividend for the **Financial Year ended March 31, 2022**

6. TRANSFER TO RESERVES:

The Company has transferred **Net Profit of Rs. 5,819.05/-** to the reserves.

7. WEB LINK OF ANNUAL RETURN:

The Company doesn't have any functional website. Therefore, no need of publication of Annual Return.

8. DETAILS OF SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES:

Your Company does not have any subsidiary, joint venture or associate company which have become or ceased to be one during the year under review.

9. NUMBER OF BOARD MEETINGS:

The details of the meetings of the Board of Directors of the company held during the **Financial Year ended March 31, 2022** have been detailed below:

Dates of Board Meetings and Attendance of each director at Board Meeting	Priti Dhananjay Shah	Rupanshi Dhananjay Shah
Tuesday, March 01, 2022	Yes	Yes
Thursday, March 03, 2022	Yes	Yes
Total No of Board Meetings attended	Two	Two

10. PARTICULARS OF LOAN(S), GURANTY(S) AND INVESTMENT(S) UNDER SECTION 186:

During the **Financial Year ended March 31, 2022**, the Company has not given any loan to any other Company including Associate Concern.

11. PARTICULARS OF CONTRACT(S) OR ARRANGEMENT(S) WITH RELATED PARTIES:

All the Related Party Transactions entered during the financial year were on arm's length basis and were in the ordinary course of business. Your Company had not entered into any transactions with the related parties which could be considered material in terms of section 188 of the Companies Act, 2013.



MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934; **Email:** medushop.priti@gmail.com

Registered Office: 0-159, Floor-1, Kalyandas Udyog Bhavan, Sh Tandel Marg, Near Century Bhavan, Mumbai – 400025

Accordingly, the disclosure of the Related Party Transactions required under the section 134(3)(h) of the Companies Act, 2013 in form AOC-2 is not applicable.

12. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNING AND OUTGO:

The particulars relating to conservation of energy, technology absorption, foreign exchange earnings and outgo, as required to be disclosed under section 134(3)(m) of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014 are as follows.

I. Conservation of Energy:

Your Company being engaged is taking all necessary steps to conserve the natural resources and to adopt environmental friendly measures including steps in the direction to promote green initiative.

II. Research & Development (R&D)

Specific R&D Activities: There is no research and development activity.
Benefits derived as a result of above R & D: N.A.
Future Plan of Action: NIL
Expenditure on R & D: NIL

III. Technology Absorption, Adaption and Innovation:

Efforts in brief made towards Technology Absorption etc.: NIL
Benefits derived as a result of above: N.A.
Technology Imported, year of import and has technology been fully absorbed? If not fully absorbed, areas where this has not taken place, reasons thereof and future plan of action: N.A.

IV. Foreign exchange earnings and outgo:

During the period under review, there was no foreign outflow from your company and it had no foreign exchange earnings.

13. RISK MANAGEMENT POLICY:

The Company has developed a very comprehensive risk management policy and the same is reviewed by the Management at periodical intervals, about the risk assessment and minimization procedures adopted by the management. At the corporate level major risks are reviewed by the Directors and directions in this regard are issued accordingly.



MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934; **Email:** medushop.priti@gmail.com

Registered Office: 0-159, Floor-1, Kalyandas Udyog Bhavan, Sh Tandel Marg, Near Century Bhavan, Mumbai – 400025

14. DEPOSITS:

The Company has not accepted any deposit within the meaning of Section 73 of the Companies Act, 2013 during the period under review.

15. CORPORATE SOCIAL RESPONSIBILITY (CSR) POLICY:

The Company is not falling within the criteria of Section 135 of the Companies Act, 2013 and hence the Company is not required to form CSR committee.

16. DIRECTOR RESPONSIBILITY STATEMENT:

Your Directors state that:

- a) In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- b) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The directors had prepared the annual accounts on a going concern basis; and
- e) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

17. COST AUDITORS:

Company does not fall within the purview of Section 148 of the Companies Act, 2013 and hence there is no requirement for the Company to appoint Cost Auditor **Financial Year ended March 31, 2022.**

18. INTERNAL AUDITORS:

Company does not fall within the purview of Section 138 of the Companies Act, 2013 and hence there is no requirement for the Company to appoint Internal Auditor for the **Financial Year ended March 31, 2022.**



MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934; **Email:** medushop.priti@gmail.com

Registered Office: 0-159, Floor-1, Kalyandas Udyog Bhavan, Sh Tandel Marg, Near Century Bhavan, Mumbai – 400025

19. SECRETARIAL AUDITORS:

Company does not fall within the purview of Section 204 of the Companies Act, 2013 and hence there is no requirement for the Company to appoint Secretarial Auditor for the **Financial Year ended March 31, 2022.**

20. AUDITORS:

MNJ and Associates (FRN: 130772W) were appointed as Statutory Auditors of your Company in the first Board Meeting to hold the office till First Annual General Meeting. The Board recommends their appointment from the conclusion of the first Annual General Meeting till the conclusion of Sixth Annual General Meeting. The Ministry of Corporate Affairs vide its notification dated May 07, 2018, has dispensed with requirement of ratification of Auditor. Hence approval of Members for the ratification of Auditor is not being sought at the ensuing Annual General Meeting.

The Report given by the Auditors on the financial statements of the Company forms part of this Report. There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their Report.

Your Company has received a confirmation from the said Auditors to the effect that their appointment, if made at the ensuing Annual General Meeting would be in accordance with the provisions of Section 141 of Companies Act, 2013.

21. DECLARATIONS AND CONFIRMATIONS:

Your Company has maintained adequate internal financial control systems, commensurate with the size, scale and complexity of its operations and ensures compliance with various policies, practices and statutes in keeping with the organization's pace of growth and increasing complexity of operations.

The Directors have devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards and that such systems are adequate and operating effectively.

There were no significant and material orders passed by the Regulators or Courts or Tribunals impacting the going concern status and Company's operations in future.

22. DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013:

The Company is committed to provide a safe and conducive work environment to its employees.

Your Directors further state that during the year under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.



MEDUCLINIC HEALTHCARE PRIVATE LIMITED

CIN: U80301MH2022PTC376934; **Email:** medushop.priti@gmail.com

Registered Office: 0-159, Floor-1, Kalyandas Udyog Bhavan, Sh Tandel Marg, Near
Century Bhavan, Mumbai - 400025

23. ACKNOWLEDGMENT:

The Directors place on record their sincere appreciation of the unstinted co-operation received during the year under review from the employees, customers, authorities, bankers, all other stake holders and look forward to their continued support and co-operation in future as well.

By order of Board

For Meduclinic Healthcare Private Limited,

Priti Dhanraj

Priti D Shah
Director
DIN: 08124259

Rupanshi Shah

Rupanshi D Shah
Director
DIN: 02896613

Place: Mumbai
Date: July 19, 2022

Shivam kumar urmaliya

Company Secretary

ACS No.: A69307

291, Vill., Shivrajpur, Satna - 485447, Madhya Pradesh

Contact no. 7581881226

Email: shivammypage@gmail.com

Date: September 14, 2022

To,
The Board of Directors,
Moxsh Overseas Educon Limited
159/160, Kaliandas Udhyog Bhavan,
Century Bazar,
Prabhadevi, Mumbai,
Mumbai City - 400025,
Maharashtra, India


Dear Sir/Madam,

Subject: Proposed Initial Public Offer of Moxsh Overseas Educon Limited ("Company") consisting of Fresh Issue.

I, Shivam K. Urmaliya, s/o Shesh Narayan Urmaliya, residing at 291, Vill., Shivrajpur, Satna - 485447, Madhya Pradesh, India do hereby give consent to my name being included as "**Company Secretary and Compliance Officer**" of the Company in the Draft Prospectus/ Prospectus to be filed with Securities and Exchange Board of India ("SEBI"), Stock Exchange(s), Registrar of Companies ("ROC") and other regulatory authorities, as may be required, pursuant to Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations ("SEBI ICDR Regulations") and other applicable laws, as amended from time to time.

I also authorize the Company to deliver a copy of this letter of consent to SEBI, Stock Exchange(s), ROC and other regulatory authorities, as may be required, pursuant to SEBI ICDR Regulations and other applicable laws, as amended from time to time.

Yours faithfully,



Shivam K. Urmaliya
Company Secretary and Compliance Officer
ACS No.: A69307



MNJ & Associates

Chartered Accountants

204, Vishal Apartment,
TPS Road No. 56, Borivali West.
Mumbai - 400092

Contact No.: 9372585419 Email: info@mnjca.com

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF MEDUCLINIC HEALTHCARE PRIVATE LIMITED

Report on the Audit of the Financial Statements

Opinion


We have audited the accompanying financial statements of MEDUCLINIC HEALTHCARE PRIVATE LIMITED ("the Company"), which comprise the Balance Sheet as at March 31, 2022, the Statement of Profit and Loss for the period ended on that date, and a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its financial performance for the period ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made



by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701 is not applicable to the Company as it is an unlisted company

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report, and Shareholder's Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial



statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls unless it is exempted under Notification.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However,



future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid financial statements comply with the accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.



- e) On the basis of the written representations received from the directors as on March 31, 2022, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) As required by Section 197 (16) of the Act, we report that, the Company has not paid any remuneration to its directors during the period which requires compliance with the provisions and limits laid down under Section 197 read with schedule V of the Act.
- g) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, same is not applicable to the Company.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigation, which would impact its financial position.
 - ii. The Company did not have any long-term contract including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts, which were required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.



v. The Company has neither declared/proposed nor paid any dividend during the period.

2. As required by the 'the Companies (Auditors' Report) Order, 2020 ("the Order")', issued by the Ministry of Corporate Affairs in terms of sub-section (11) of Section 143 of the Act (hereinafter referred to as the "Order"), and on the basis of such checks of the books and records of the Company, based on the information and explanations given to us, we are of the opinion that statement on the matters specified in paragraphs 3 and 4 of the Order, is not applicable to the Company since the company is a "Small Company " as defined in Section 2(85) of the Act.

For **MNJ AND ASSOCIATES**
Chartered Accountants
Firm Registration No: 130772W



R. Rajendra Shah
RAJENDRA SHAH

Partner
(Membership No. 111647)
UDIN :22111647ANEVIE5021

Place: Mumbai
Date: 19/07/2022